IRVINE, Calif.--(EON: Enhanced Online News)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against USANA Health Sciences, Inc. (“USANA” or the “Company”) (NYSE: USNA) concerning possible violations of federal securities laws.
“compliance with the Foreign Corrupt Practices Act”
If you purchased shares of USANA and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
USANA develops, manufactures and sells nutritional and personal care products primarily to reduce the risk of chronic degenerative disease.
On February 7, 2017, USANA revealed that it will be starting an internal investigation of its Chinese subsidiary, BabyCare Ltd. (“BabyCare”).
In particular, the Company’s investigation concerns “compliance with the Foreign Corrupt Practices Act” as well as “BabyCare’s expense reimbursement policies.”
When this information was revealed to the investing public, the value of USANA declined, causing investors harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.